NASDAQ:CLVS - Clovis Oncology Stock Price, Forecast & News

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Clovis Oncology (NASDAQ:CLVS) announced its quarterly earnings results on Monday, February, 24th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the Zacks' consensus estimate of ($1.71) by $0.10. The biopharmaceutical company earned $39.31 million during the quarter, compared to the consensus estimate of $38.79 million. Clovis Oncology had a negative net margin of 280.01% and a negative return on equity of 1,576.32%. View Clovis Oncology's Earnings History.

Clovis Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Clovis Oncology.

Clovis Oncology issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $38.3-39.3 million, compared to the consensus revenue estimate of $40.39 million.

15 equities research analysts have issued 12-month price targets for Clovis Oncology's shares. Their forecasts range from $4.00 to $36.00. On average, they expect Clovis Oncology's share price to reach $19.91 in the next twelve months. This suggests a possible upside of 166.5% from the stock's current price. View Analyst Price Targets for Clovis Oncology.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 1 sell rating, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Clovis Oncology.

News coverage about CLVS stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clovis Oncology earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Clovis Oncology.

Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Micron Technology (MU), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Intercept Pharmaceuticals (ICPT), Alibaba Group (BABA), Incyte (INCY), Amarin (AMRN), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Clovis Oncology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (9.23%), State Street Corp (6.68%), Candriam Luxembourg S.C.A. (1.82%), Pinnacle Associates Ltd. (1.15%), Charles Schwab Investment Management Inc. (0.58%) and California Public Employees Retirement System (0.44%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.

CLVS stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Panagora Asset Management Inc., Bank of New York Mellon Corp, First Midwest Bank Trust Division, Candriam Luxembourg S.C.A., KBC Group NV, Janney Montgomery Scott LLC and Jacobs Levy Equity Management Inc.. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and Paul Edward Gross. View Insider Buying and Selling for Clovis Oncology.

CLVS stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Pinnacle Associates Ltd., Palo Alto Investors LP, California Public Employees Retirement System, Rafferty Asset Management LLC, Creative Planning, Nisa Investment Advisors LLC and Alpine Global Management LLC. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLVS stock can currently be purchased for approximately $7.47.

Clovis Oncology has a market capitalization of $409.43 million and generates $143.01 million in revenue each year. The biopharmaceutical company earns $-368,010,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis. View Additional Information About Clovis Oncology.

The official website for Clovis Oncology is http://www.clovisoncology.com/.

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]